Clinical Trial Update: A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates furmonertinib in combination with chemotherapy for non-small cell lung cancer with leptomeningeal metastasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Jiangsu Province Nanjing Brain Hospital | Conditions: NSCLC | Phase 2 | Status: UNKNOWN